Services: Pharmaceutical medicines, vaccines, consumer healthcare; specialty medicines in HIV, oncology, respiratory; vaccines for hepatitis, HPV, meningitis.
Q2 2026 earnings call
During its Q3 2026 earnings presentation on October 28, 2026, GSK confirmed that its multi-year £1.9 billion (.5 billion) Accelerate Growth cost-reduction program will impact support functions at its London global headquarters. The central administrative streamlining follows 1,217 positions put at risk across R&D and manufacturing in Belgium and the closure of a German vaccine facility, with freed-up capital channeled directly into late-stage clinical trials and bench research.
GSK initiated plans to cut up to 1,217 R&D, management, and support roles (~14% of its Belgian workforce) across its vaccine division hubs in Wavre, Rixensart, and Gembloux under CEO Luke Miels' £1.9B ($2.5B) 'Accelerate Growth' cost-reduction program.
GSK announced plans to lay off approximately 650 employees and close its traditional egg-based seasonal influenza vaccine manufacturing plant in Dresden, Germany, citing global supply-chain overcapacity.
During Q3 earnings, GSK CEO Luke Miels disclosed that its £1.9 billion ($2.5 billion) restructuring program will trim support functions at London headquarters, following over 1,200 cuts in Belgium and facility closures in Germany.
GSK shares come under pressure from weaker vaccine sales
GSK talks through Hibsago launch as it reports out mixed Q3
GSK vaccine sales miss expectations amid falling demand from adults
GSK’s B7-H3 ADC drives 67% cancer risk reduction in phase 3
GSK planning 1,200 job cuts in Belgium, says paper
Amid bepirovirsen triumph, GSK scraps trial of next-gen therapy
The first data from GSK's international trial of B7-H3-targeted ADC ris-rez in small cell lung cancer back up earlier results from a Chinese study.
FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
The layoffs across GSK's Belgium sites come on the heels of the pharma's planned shuttering of its German vaccine manufacturing site, which prompted job cuts for about 650 employees.
GSK drinks in Chai’s AI models after wet-lab validation
GSK is committing $800 million to expand its R&D and manufacturing footprint in Pennsylvania, deepening its US investment as pharma manufacturers face pressure to onshore production.
GSK continues stockpiling Wave drugs with liver-focused program
GSK has been operating a strategy of “balancing the West and the East” since the British pharma’s eyes were opened to the potential of licensing drugs from China a few years ago, according to an executive.
News from Fierce Pharma: GSK to shutter flu vaccine manufacturing site
GSK prepares for patent cliff with $2.5B cost-cutting plan
GSK, AI biotech Relation pen $110M biological datasets pact
GSK's Jideytro (belantamab) regimen won FDA accelerated approval for ROS1-positive lung cancer, validating the company's $10.6B acquisition earlier this year.
GSK's $10.6 billion Nuvalent bet pays off early as the FDA approves its lung cancer drug.
GSK's $10.6B Nuvalent deal delivers its first-ever lung cancer FDA approval with Jideytro (zidesamtinib) for ROS1-positive NSCLC.
GSK is shelving its cough drug camlipixant that it acquired in a $2 billion deal.
A $10 billion M&A deal pays off with GSK's first lung cancer drug FDA approval (Jideytro / zidesamtinib).